Translational Science in Prostate Cancer COE

Polyaneuploid Cancer Cells Drive Metastasis and Resist Treatments in Prostate Cancer - Sarah Amend

Details
Sarah Amend discusses research on polyaneuploid cancer cells (PACCs) and their role in metastasis, published in Molecular Cancer Research. Dr. Amend explains how cancer cells under stress enter an adaptive endocycling state, increasing dramatically in size and genomic content without dividing. The discussion highlights their findings that cells in the PACC state are preferentially found in circula...

Trial Library Platform Expands Clinical Trial Access for Patients - Hala Borno

Details
Andrea Miyahira interviews Hala Borno about Trial Library, an innovative platform developed to improve access to clinical trials and increase diversity in trial participation. The technology-enabled service connects community providers with clinical trials while offering comprehensive patient navigation support, addressing social determinants of health and practical barriers to trial participation...

Single-Cell Analysis Reveals Heterogeneity in Treatment-Resistant Prostate Cancer - Samir Zaidi

Details
Samir Zaidi joins Andrea Miyahira to discuss a paper on single-cell analysis of treatment-resistant prostate cancer. Using advanced single-cell technologies, the study reveals significant diversification in gene programs within castrate-resistant prostate cancer, identifying multiple tumor states and transcription factor networks that emerge as resistance mechanisms to androgen receptor signaling...

Notch Signaling Suppresses Neuroendocrine Differentiation in Advanced Prostate Cancer - Sheng-Yu Ku

Details
Andrea Miyahara speaks with Sheng-Yu Ku about a Journal of Clinical Investigation publication examining the role of Notch signaling in neuroendocrine prostate cancer. The research demonstrates that Notch signaling acts as a tumor suppressor in neuroendocrine prostate cancer by suppressing neuroendocrine differentiation and inducing prostate luminal lineage development. Dr. Ku's work reveals how No...

Elevated CBP/p300 Expression Linked to Poor Outcomes in Advanced Prostate Cancer - Ayesha Shafi

Details
Andrea Miyahira speaks with Ayesha Shafi about a study on AR coactivators CBP/p300 in prostate cancer. The research reveals that CBP/p300 expression increases as prostate cancer progresses to castration-resistant stages, correlating with poor patient survival. Through various preclinical studies, Dr. Shafi demonstrates that CBP/p300 plays a crucial role in DNA repair, particularly in homologous re...

Comprehensive Atlas Details Prostate Cancer Chromatin Patterns - Raunak Shrestha

Details
Raunak Shrestha discusses a published study on chromatin accessibility in advanced prostate cancer. The research, which represents the largest collection of ATAC-seq profiles in metastatic prostate cancer to date, reveals distinct chromatin accessibility patterns across different cancer subtypes. The study identifies 203 transcription factors associated with various metastatic prostate cancer subt...

Olaparib Effective in BRCA2-Altered Biochemical Recurrence Post-Prostatectomy in Phase 2 Study - Catherine Handy Marshall

Details
Cathy Marshall discusses a non-randomized clinical trial evaluating olaparib without androgen deprivation therapy for high-risk biochemically recurrent prostate cancer following prostatectomy. The study shows promising results, particularly for patients with BRCA2 alterations, where all patients demonstrate PSA-50 responses. The conversation explores the trial design, patient outcomes, and safety...

Humanized Mice Reveal Role of Immune System in Prostate Cancer Therapy Efficacy - Steven Kregel

Details
Andrea Miyahira hosts Steven Kregel to discuss a published paper on humanized mouse models for metastatic prostate cancer. Dr. Kregel discusses the challenges of modeling prostate cancer in mice and introduces humanized mouse models that better recapitulate human immune responses. He explains how these models, developed using human hematopoietic stem cells, allow for the study of cancer therapies...

Antibody Drug Conjugate FOR46: Targeting CD46 in mCRPC in Phase 1b Trial - Nonna Shakhnazaryan

Details
Nonna Shakhnazaryan discusses a phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting CD46, in combination with enzalutamide for metastatic castration-resistant prostate cancer. The study establishes the maximally tolerated dose and shows promising results, with 71% of patients experiencing PSA declines, including some who previously progressed on enzalutamide. The med...

Extracellular Vesicles in Prostate Cancer: Multi-Omic Liquid Biopsy - Irene Casanova-Salas & Joaquin Mateo

Details
Andrea Miyahira discusses with Irene Casanova-Salas and Joaquin Mateo a Cancer Cell publication on using circulating tumor extracellular vesicles (EVs) to monitor metastatic prostate cancer evolution. The researchers describe their novel method for analyzing both DNA and RNA from EVs in patient plasma samples. They highlight the advantages of EV analysis over traditional ctDNA, including the abili...